Schmidt J, Albrecht S, Petterich N, Fechner J, Klein P, Irouschek A
Anästhesiologische Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen.
Anaesthesist. 2007 Oct;56(10):992-1000. doi: 10.1007/s00101-007-1226-5.
Priming can significantly shorten the onset of nondepolarizing neuromuscular blocking agents (NNBA) measured at the adductor pollicis muscle (APM). In spite of the known risks, priming is very popular especially in cases where NNBAs with a long onset time are used. However, there are no data regarding the onset of action for a priming technique measured at the laryngeal muscles although these muscles are of great importance for conditions of intubation and patient safety. The aim of this study was to compare a bolus application and a priming technique with respect to the laryngeal onset time and peak effect.
After approval of the local ethics committee and written informed consent, 36 patients undergoing elective thyroid surgery were enrolled in the study. Anesthesia was induced and maintained with a target controlled infusion of propofol (target concentration 2.7-6.0 microg/ml) and infusion of remifentanil (0.25-0.75 microg/kgbw/min). After loss of consciousness, a tube with a surface electrode was placed into the trachea without the application of any neuromuscular blocking agent. Neuromuscular monitoring consisted of evoked electromyography (EMG) of the laryngeal adductor muscles via the surface electrode and evoked acceleromyography (TOF Guard) of the right adductor pollicis muscle (APM). After transcutaneous stimulation of the recurrent laryngeal nerve and ulnar nerve, either 0.9% NaCl followed by 0.1 mg/kgbw cisatracurium after 3 min (bolus group, n=12), a priming dose of 0.01 mg/kgbw cisatracurium followed by 0.09 mg/kgbw 3 min later (low dose priming group, n=12) or a priming dose of 0.015 mg/kgbw cisatracurium followed by cisatracurium 0.085 mg/kgbw 3 min later (high dose priming group, n=12) were injected. Lag time, onset time and peak effect of NMB were recorded and compared between the groups.
Demographic data, lag time and peak effect were comparable between the three groups. Onset time at the laryngeal muscles was significantly shorter in the high dose priming group (80+/-17 s), when compared to the low dose priming group (128+/-23 s) and bolus group (142+/-29 s). Onset time at the APM was also significantly shorter in the high dose priming group (154+/-35 s), when compared with the bolus group (226+/-76 s). The recovery of the neuromuscular function measured at the APM showed no differences between the groups.
Our results show that only high dose priming of cisatracurium can significantly shorten the laryngeal onset time. However, clinical routine use is not recommended due to possible side-effects.
预注法可显著缩短在内收拇肌(APM)测量的非去极化神经肌肉阻滞剂(NNBA)的起效时间。尽管存在已知风险,但预注法非常普遍,尤其是在使用起效时间长的NNBA的情况下。然而,尽管喉肌对于插管条件和患者安全非常重要,但尚无关于在喉肌测量的预注技术起效时间的数据。本研究的目的是比较单次推注应用和预注技术在喉肌起效时间和最大效应方面的差异。
经当地伦理委员会批准并获得书面知情同意后,36例行择期甲状腺手术的患者纳入本研究。采用丙泊酚靶控输注(靶浓度2.7 - 6.0微克/毫升)和瑞芬太尼输注(0.25 - 0.75微克/千克体重/分钟)诱导和维持麻醉。意识消失后,在未使用任何神经肌肉阻滞剂的情况下,将带有表面电极的导管置入气管。神经肌肉监测包括通过表面电极对喉内收肌进行诱发肌电图(EMG)监测以及对右侧内收拇肌(APM)进行诱发加速度肌电图(TOF Guard)监测。经皮刺激喉返神经和尺神经后,分别给予:3分钟后先给予0.9%氯化钠,随后给予0.1毫克/千克体重顺式阿曲库铵(单次推注组,n = 12);先给予0.01毫克/千克体重顺式阿曲库铵预注剂量,3分钟后再给予0.09毫克/千克体重(低剂量预注组,n = 12);或先给予0.015毫克/千克体重顺式阿曲库铵预注剂量,3分钟后再给予0.085毫克/千克体重顺式阿曲库铵(高剂量预注组,n = 12)。记录并比较各组神经肌肉阻滞(NMB)的滞后时间、起效时间和最大效应。
三组间人口统计学数据、滞后时间和最大效应具有可比性。高剂量预注组喉肌的起效时间(80±17秒)显著短于低剂量预注组(128±23秒)和单次推注组(142±29秒)。高剂量预注组APM的起效时间(154±35秒)也显著短于单次推注组(226±76秒)。在APM测量的神经肌肉功能恢复情况在各组间无差异。
我们的结果表明,只有高剂量预注顺式阿曲库铵才能显著缩短喉肌起效时间。然而,由于可能的副作用,不建议临床常规使用。